These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1145 related items for PubMed ID: 18380818

  • 1. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 3. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 4. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M.
    BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
    Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP.
    Clin Cancer Res; 2000 Dec 01; 6(12):4866-73. PubMed ID: 11156246
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct 01; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 13. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun 01; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 14. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F.
    Cancer; 2004 Dec 01; 101(11):2540-8. PubMed ID: 15481058
    [Abstract] [Full Text] [Related]

  • 15. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 16. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.
    Int J Clin Oncol; 2005 Apr 01; 10(2):133-8. PubMed ID: 15864700
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
    Lehmann J, Retz M, Stöckle M.
    World J Urol; 2002 Aug 01; 20(3):144-50. PubMed ID: 12196897
    [Abstract] [Full Text] [Related]

  • 18. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG.
    J Urol; 2006 Aug 01; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
    Park J, Park S, Song C, Doo C, Cho YM, Ahn H, Kim CS.
    Urology; 2007 Aug 01; 70(2):257-62. PubMed ID: 17826485
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP.
    J Urol; 2006 Dec 01; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.